Text Size

Preanalgesic Effect of Gabapentin in Total Knee Repair

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Texas Health Resources.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Texas Health Resources
ClinicalTrials.gov Identifier:
NCT00279487
First received: January 16, 2006
Last updated: February 27, 2007
Last verified: January 2006
History of Changes
  Purpose

The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.


Condition Intervention
Pain
 Drug: Gabapentin

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Texas Health Resources:

Estimated Enrollment: 60
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients undergoing total knee replacement who received pain management by the following modality:

    • Intravenous patient-controlled analgesia (IV-PCA) opioid
    • Local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml

Exclusion Criteria:

  • Age < 18 years old
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00279487

Contacts
Contact: Rob Hutchison, PharmD 214-345-2493 robhutchison@texashealth.org

Locations
United States, Texas
Presbyterian Hospital of Dallas Recruiting
Dallas, Texas, United States, 75231
Contact: Rob Hutchison     214-345-2493     robhutchison@texashealth.org    
Contact: Denise Stamos     214-345-2966     denisestamos@texashealth.org    
Principal Investigator: William Tucker            
Sub-Investigator: Jeffrey Pirinelli            
Sub-Investigator: Joy Aguwa            
Sponsors and Collaborators
Texas Health Resources
Investigators
Principal Investigator: Rob Hutchison Texas Health Resources
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00279487     History of Changes
Other Study ID Numbers: P768
Study First Received: January 16, 2006
Last Updated: February 27, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Texas Health Resources:
Patients undergoing total knee replacement who received pain management by the following modality:
IV PCA opioid
Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine

Additional relevant MeSH terms:
Gabapentin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
 Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents

ClinicalTrials.gov processed this record on May 16, 2013